SSKN has been the subject of several other research reports. Northland Securities reissued a buy rating and set a $7.00 price target on shares of STRATA Skin Sciences in a research report on Tuesday, May 14th. HC Wainwright set a $5.00 target price on shares of STRATA Skin Sciences and gave the stock a buy rating in a research report on Monday, July 8th. Finally, Zacks Investment Research cut shares of STRATA Skin Sciences from a buy rating to a hold rating in a research report on Saturday, June 1st. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $4.92.
SSKN traded up $0.08 during trading on Thursday, hitting $2.92. 14,800 shares of the stock traded hands, compared to its average volume of 46,199. The company has a 50-day moving average price of $2.49. STRATA Skin Sciences has a 12-month low of $1.86 and a 12-month high of $3.88.
STRATA Skin Sciences Company Profile
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
Featured Article: Roth IRA
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.